Therapeutic hypothermia is the most potent neuroprotectant for experimental cerebral ischemia, illustrated in a 2007 meta-analysis published in this journal. To address recent therapeutic nihilism, we systematically reviewed recent experimental literature. Quality scoring showed considerable improvement in study design. Using several outcome measures in a variety of models and species, therapeutic hypothermia was protective compared with normothermia, with powerful and statistically significant normalized treatment effect sizes, in 60 papers comprising 216 comparisons. In the past 5 years, preclinical studies of ischemic stroke re-emphasize that therapeutic hypothermia is potently effective, justifying further development in larger human clinical trials.
Introduction
Therapeutic hypothermia (TH) is the most potent neuroprotectant yet studied in animals for acute cerebral ischemia, in part because of its multiple pathophysiological targets. 1 While the therapeutic benefit of hypothermia in human stroke is under study, 2, 3 the specific logistic details for optimal therapy are not well established. A meta-analysis of pre-clinical effort was published in 2007 and systematically revisited for clinical readiness in 2010. 1, 4 Recent clinical trial failures, however, have called into question the relevance of TH as a potential neuroprotectant, prompting us to review the experimental data testing TH for acute focal cerebral ischemia since 2010. We aimed to identify whether more recent data continues to support an overall benefit of TH over normothermia (NT); if there is a differential effect of hypothermia modality (whole-body cooling, focal intra-arterial cooling, or focal cooling using a device); and what are the effects of target temperature, hypothermia duration, and the time to onset of hypothermia on the effect size.
Methods
We conducted a systematic search of the medical literature using Pubmed between 2010 and 2015, using (((cerebral) OR (brain) OR (neuron) OR (nervous) OR (neuroprotection)) AND ((ischemia) OR (ischemia) OR (stroke)) AND ((hypothermia) OR (temperature)) AND (''2010/01/01'' (Date-Publication): ''2015/12/01'' (Date-Publication))). All abstracts that reported various modalities of TH in different animal models of ischemic stroke were identified. The articles were included in the systematic analysis if they reported the treatment effect of induced hypothermia versus normothermia in animal ischemic stroke models. Each article was rated for quality by two independent readers using published criteria. 5 The following data were collected and analyzed: gender, animal species, model of focal ischemia, modality of induced hypothermia, hypothermia duration, timing between stroke induction and hypothermia initiation, the target temperature, temperature measurement model, infarct volumes, neurobehavioral scores, cerebral edema volume, numbers of cells labeled with various markers of apoptosis or necrosis. Based on recent clinical concern that minimal cooling is equivalent to moderate cooling, 6 we grouped articles based on the targeted temperature: <33 C, 33-34 C, >34 C, and by the use of whole body cooling (including mechanical or pharmacological methods) versus selective cooling with intra-arterial saline or selective cooling with an implanted intracranial device. To compare effects of TH across multiple studies with widely varying methods, we calculated the normalized mean difference treatment effect sizes. 4 The effect sizes and standard errors were summarized in a meta-analysis assuming a random effects model (REML) weighting each mean effect size by standard error. 7 Heterogeneity was tested with the Q statistic. We assessed for publication and other bias using funnel plot asymmetry, trim-and-fill analysis, and Eggers regression. 8 Meta-regression was performed using a mixed effects model with treatment onset delay, duration, and group entered as fixed factors. All analyses were completed using R version 3.2.2 and the metafor package (version 1.9-8). 9 
Results
Our initial literature search identified 1554 citations, from which we excluded reviews, editorials, comments, and duplicates leaving 1180 abstracts. We then excluded human studies, purely in vitro studies, use of hypothermia in indications other than stroke, only abstracts available (6), leaving 108 publications for detailed review; rejection reasons were in vitro (6) , no outcomes of interest (17) , absent comparison against normothermia (20) , global ischemia (6). One additional paper was included after manual search of the references in the included papers. The final study group included 60 papers (full list in Appendix 1). Studies were done in rats (82%), mice (15%), and one study each using baboons or pigs. While two articles did not specify the gender, the rest of the studies involved males only. In studies of additional neuroprotective therapies (rt-PA, magnesium, protein transduction domain fused FNK (PTD-FNK), pethidine, granulocyte colony stimulating factor, dexmedetomidine, xenon, citicoline, phenotiazines, insulin-like growth factor-1), we included the hypothermia-only group, or the combination group if the additional agent alone exhibited no significant protective benefit. The most frequently used model of focal cerebral ischemia was middle cerebral artery temporary (ranging between 7 and 180 min) or permanent occlusion (tMCAo or pMCAo, respectively), followed by endothelin-1 infusion, two-vessel occlusion model of forebrain ischemia, and photothrombotic occlusion of cerebral microvessels. Modality of TH varied between selective hemicranial cooling by endovascular cold saline or focal intracranial implanted cooling device, whole body cooling by endovascular or surface methods, and pharmacologic agents alone.
Quality scores (8 points maximum) ranged from 2 to 8 (median (IQR) ¼ 4 (3,5)) with no differences among the study groups; there was no relationship between quality score and effect size, although the sample size is relatively small. Nearly all (58/61, 98%) studies reported the species used; only 11 (18%) included a sample size calculation or power estimation. The quality of the papers included here is significantly improved over the 2007 meta-analysis, in which out of 101 publications, the number published in peer review was only 86; randomization of subjects 36; blinded conduct of outcomes was 38 (personal communication M. McLeod). The result of our quality scoring is attached as a Supplementary table. Target cooling temperatures ranged from 14 to 35 C. The duration of HT ranged from 0 to 24 h, and the delay to treatment start ranged from À60 to 180 min. The duration of cooling did not differ significantly among the various studies of whole body cooling. There was a nominal difference, however, comparing TH duration (mean AE SD) between studies using focal intra-arterial cooling (97 AE 207 min, n ¼ 11) versus whole body cooling (440 AE 702 min, n ¼ 73, NS by t-test). The results by group are shown in Table 1 .
Lesion volume was estimated using the 2,3,5-triphyenyl-2 h-tetrazolium chloride (TTC) method, serial histology sections, or magnetic resonance imaging. We computed the normalized mean difference in stroke volumes comparing normothermia treatment to all modalities of TH after focal stroke. Across all target temperatures and cooling modalities, in a total of 91 comparisons, there was a powerful and statistically significant treatment effect (Supplementary Figure 1 ) (mean (95% CI)) 44.4% (39.3, 49.5). There was considerable heterogeneity (Q df,90 ¼ 10156, p < .0001), however. The funnel plot clearly suggested that smaller studies yielded larger effect size estimates (Egger regression z ¼ 6.90, p < .0001), but there was no evidence of negative publication bias using trim-and-fill analysis. One possible source of heterogeneity is the variation in delay time (time from stroke onset to start of cooling) and the duration of cooling. Using metaregression, however, neither variable significantly influenced the estimated treatment effect size. The data therefore suggests a powerful treatment benefit from TH despite inter-laboratory variation, notably cooling modality, species, stroke model, and target temperature.
To determine whether target temperature influenced outcome, the studies were grouped by target temperature: less than 33 C (n ¼ 23 studies), 33-34 C (n ¼ 34), greater than 34 C (n ¼ 16). In addition, we separated studies of intra-carotid saline (n ¼ 11) and intracranial cooling devices (n ¼ 7) as separate study groups. Using meta-regression, all levels of TH were highly protective, compared with NT, irrespective of cooling modality but no single temperature level was superior to any other. Similarly, among the included studies, meta-regression failed to identify an effect of treatment delay or duration on infarct volume. The forest plot of treatment effect sizes for intra-carotid saline treatment is shown in Figure 1 .
The effects on neurobehavioral scores (Supplementary Figure 2) were similar to the effect of TH on lesion volumes, with an estimated effect size of (mean (95% CI)) 30.3 (25.0, 35.7) % in a total of 77 comparisons. The estimate showed considerable heterogeneity (Q 76 ¼ 4597, p < .0001), but no evidence of publication bias: smaller trials gave smaller treatment effect estimates. Using meta-regression, there was no effect on behavior scores due to target temperature depth, delay, or duration.
There were many fewer studies of the effect of TH on cerebral edema, which was measured in a variety of ways and over a wide variety of time points, in some cases too early to detect benefit. Nevertheless, we used reported estimates from magnetic resonance imaging, leakage of serum markers (Evans Blue), or wet/dry weight. Generally, TH was superior to NT with mean (95% CI) treatment effect of 35.0 (20.4, 49.5) % in 20 comparisons ( Supplementary Figure 3) . Heterogeneity was significant, Q 19 ¼ 1937, p < 0.001 and the test for funnel asymmetry was significant, z ¼ 4.7, p ¼ 0.0002. Using meta-regression, no difference could be detected among target temperature or treatment duration.
Some investigators have studied the effect of TH on the presence of damaged cells, stained for caspase 3, TUNEL to document apoptosis, bromodeoxyuridine (BRDU) as a marker of proliferating cells, or Fluorojade to document necrosis ( Supplementary Figure 4) . In general, in 28 comparisons, all levels of TH showed significant reduction in the number of positively stained cells, with a mean (95% CI) effect size of 118.5 (60.4, 176.6) %. There was no difference among the levels of TH or intracarotid saline. There was variation in the treatment protocols, with treatment delays ranging from 0 to 120 min and treatment durations ranging from 0 to 3 h. One study sought to identify an effect on neurogenesis using markers for dividing cells (BRDU), but, in this study, TH did not impair neurogenesis. 8 These investigators found a highly significant reduction in microglial proliferation, with diminishing benefit over longer delay times.
Discussion
Although mechanistically and historically promising in animal models of global and focal cerebral ischemia, clinical application of TH in ischemic stroke faces ongoing hurdles. Earlier meta-analyses of pre-clinical results documented that TH is associated with improved outcomes 1,4 but given recent clinical failures, we asked whether recent, perhaps more rigorous experimental data continue to confirm a positive treatment effect. We used state-of-the-art meta-analysis techniques as proposed for rigorous evaluation of preclinical data and analyzed only trials published in the past 5 years. 7 We found-across a wide variety of models, species, and protocols-that TH continues to show robust benefit, with an estimated normalized median treatment effect size of 10 to 80% depending on the outcome measure used (Figure 1(a) ). The experimental quality of the trials we analyzed was reasonably good (median 4 out of possible 8 points; see Supplementary table) and there has been a trend in the last 5 years toward improved quality (blinding, randomization) in preclinical trials. Thus, TH remains a promising putative neuroprotectant that requires further development in clinical application.
We found considerable heterogeneity in these metaanalyses (Figure 1 and Supplementary figures) . Such heterogeneity may be due to a variety of causes, most worrisome of which is publication bias; using funnel plots and trim-and-fill analysis, we found no evidence For comparison to prior studies-which primarily focused on infarction volume compared among trials-we summarized the key properties of the trials from which we extracted normalized mean differences in infarction volume. We included 91 unique comparisons. Studies of whole body cooling (surface or pharmacological) were grouped according to the targeted body temperature. Studies that used intracarotid cold saline or skull/dural local cooling devices were grouped separately. The mean AE SD delay time (delay from ischemia onset to start of cooling) and the duration of cooling are summarized. Using one-way ANOVA and Tukeys HSD post-hoc test, we found no significant differences among the groups, although the duration of intra-carotid hypothermia was nominally shorter than the whole body cooling groups. All results are given as mean AE SD Figure 1 . (a) Effect of therapeutic hypothermia on lesion volume, brain edema, and behavioral scores. The treatment effect sizes were estimated from a random effects model meta-analysis of reported endpoints after computing the normalized mean difference for each outcome. 7 The groups are defined in the ''Methods'' section. For the endpoints stroke volume, cerebral edema, and behavior scores, the mean normalized mean difference is shown with standard error for each group. There are no statistically significant differences among the groups, although hypothermia is superior to normothermia across all measures and all target temperatures. (b) Forest plot of stroke volume after intracarotid cold saline. We computed the normalized mean difference in stroke volumes comparing normothermia treatment to intra-carotid cold saline infused after focal cerebral ischemia. There were 11 studies with a combined estimated treatment effect size of 50.7% (95% CI: 37.9, 63.5), which is highly statistically significant (p < 0.001). The heterogeneity was highly significant, Q 10 ¼ 147, p < 0.001 suggesting that there is significant variation among the publications, but after trim-and-fill analysis, 7 we found an estimated number of missing studies to be 0 (SE ¼ 2.1), suggesting the absence of negative publication bias. On possible source of heterogeneity is the variation in delay time (time from stroke onset to start of cooling) and the duration of cooling. Using meta-regression, however, neither variable significantly influenced the estimated treatment effect size. The data therefore suggests a powerful treatment benefit from intracarotid cold saline despite inter-laboratory variation, notably species, stroke model, and target temperature.
that negative trials are systematically missing from the literature. On the other hand, there is an obvious trend toward smaller effect sizes in trials using larger sample sizes, a well-recognized phenomenon. The most obvious source of heterogeneity is that we included studies spanning such a wide range of methods and techniques.
To minimize potential error, we used a random effects model in the analysis and then used meta-regression to attempt to isolate known sources of experimental variation: target temperature, treatment delay, and treatment duration. We also examined species and cooling modality (data not shown). None of these variables explained a significant amount of variation in the treatment effect sizes, but the available data set is relatively small given the large number of co-variates we examined and a Type II error is possible. On balance, therefore, the data support the conclusion that TH is highly protective; that smaller studies over-estimate the treatment benefit; and that much larger studies will be needed to isolate the effects-if any-of target temperature depth, treatment delay, and treatment duration.
Since the previous meta-analysis of pre-clinical TH studies, new data suggest that TH via intracarotid cold saline administration can be initiated at a later time point and be conducted for a shorter duration to obtain similar functional outcomes compared with the whole body cooling (Figure 1 ). The advent of intraarterial embolectomy as a standard treatment approach in human stroke patients, 10 makes this TH strategy more applicable and feasible in clinical practice. Lower cooling duration, as well as selective cooling, could potentially reduce the systemic complications associated with extended hypothermia and whole body cooling, including cardiovascular derangements and infections. 11, 12 While selective hypothermia by intracarotid saline administration offers advantages, intracranial implanted cooling devices were inferior to whole body cooling in this analysis.
Differences in design and methodological quality between the animal studies constitute a limitation of this systematic analysis. The underlying quality of the analyzed studies was good overall, but there was considerable variation in rigor, which has been shown to influence treatment effect size. We used the normalized mean difference of all treatment effects to allow pooling and statistical comparisons, but this approach ignores critical differences in methodology among the trials. 7 Perhaps reflecting investigator awareness that shallower target temperatures require longer durations, treatment duration was longer if target temperature was higher than 34 C and this introduces an obvious bias into our meta-regression since temperature and duration were not independent; further randomized investigations of target depth, treatment delay, and duration must be completed. Although investigated in a limited number of studies, additional presumed neuro-protective therapy administered concomitant with TH did not provide better functional or histological outcomes compared with TH alone.
In conclusion, using rigorous meta-analysis techniques, we showed the latest preclinical data are of higher quality than previous reports, and the data continue to support consideration of TH for cerebral ischemia in larger clinical trials of acute ischemic stroke. By increasing the time window to therapy initiation and decreasing the treatment duration, selective intracarotid cold saline administration brings increased feasibility, potentially better outcomes and perhaps fewer complications compared with the whole body cooling. This treatment modality might also provide a more practical approach, including a larger stroke patient population.
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